IMPACT CHINA II: PHARMACEUTICAL R&D GLOBAL SUMMIT

MAY 21 - 24, 2006
SHANGRI-LA HOTEL BEIJING
BEIJING, CHINA

Your Gateway to the World’s Fastest Growing Pharmaceutical Market

TO REGISTER OR FOR MORE INFORMATION, VISIT WWW.SRINSTITUTE.COM/CHINA
Dear Colleagues:

The growing impact that China is having on the global pharmaceutical marketplace is currently being felt by the industry on a wide scale in areas such as outsourcing, clinical trials, manufacturing and more recently, drug discovery and development. But what should the industry realistically expect from their investments in China in the coming years?

Impact China II will separate the hype vs. reality surrounding the Chinese market by providing attendees an unbiased look into the current state of the industry.

This is the best conference on China in 2006. Over 250 industry executives representing over 100 companies and 10 different countries attended the inaugural meeting last September in Shanghai.

We have doubled the number of speakers to over 75, each of who will give their “on-the-ground” views addressing timely and pressing issues including:

- A Comparison of China vs. India, Japan, Asia-Pacific
- Intellectual Property & Patent Protection/Enforcement
- Venture Capital Investment, Technology Valuation/Transfer, East/West M&As
- The Emerging Drug Discovery Landscape in China
- Outsourcing Preclinical & Clinical R&D to China
- Manufacturing, APIs and Generics in China
- Regulatory Insights in Clinical Trials, GMPs and Drugs/Biologics
- Business Practices, Commercialization and Marketing Strategies in the Chinese Market
- East/West Partnerships, Licensing, and Business Development Strategies

We have arranged exclusive off-site visits to local biotechs and manufacturing sites in Beijing’s prestigious ZhongGuanCun Life Science Park to give attendees a first-hand look at the local facilities.

Join and network with hundreds of your colleagues from the US, EU, China and Asia Pacific at Impact China II this May 21-24 in Beijing for 2006’s most informative and best attended event on the world’s fastest growing pharmaceutical market.

On behalf of the Conference Advisory Board…Welcome to Beijing!

Sincerely,

Jon E. Liong, Senior Vice President, Life Sciences
STRATEGIC RESEARCH INSTITUTE

DISTINGUISHED CONFERENCE ADVISORY BOARD:

Hui Min Chen, Ph.D.
Senior Research Scientist
WYETH

Li Chen, Ph.D.
Head of Research
ROCHE R&D CENTER CHINA

Ling Chen, M.D., Ph.D.
Director General & Professor
GUANGZHOU INSTITUTE OF MEDICINE & HEALTH

Mark Engel
Chief Executive Officer & President
EXCEL PHARMASTUDIES

James Foley, Ph.D.
Vice President, Business Development
BRISTOL-MYERS SQUIBB

Zhi Hong, Ph.D.
Vice President of Drug Discovery
VALENT PHARMACEUTICALS

Steven Hutchins, Ph.D.
Senior Director, Global Basic & Pre-Clinical Sourcing
MERCK & CO.

Kewen Jin, Ph.D.
Managing Partner
AURA PARTNERS

Ting Lei
Director
BEIJING PHARMA & BIOTECH

Minghua Lu
Chief Executive Officer
PACIFIC GENUITY

Jay Mei, M.D., Ph.D.
Associate Director, Clinical Research-Oncology Global Development
JOHNSON & JOHNSON PRD

Lorenz Ng, M.D., Ph.D.
V.P., Research & Alliance & Business Development - Asia Pacific
ELI LILLY ASIA

Glenn Rice, Ph.D.
President & CEO
BRIDGE PHARMAECUTICALS

Guozhong Rui
Director
CHINA PHARMACEUTICAL TECHNOLOGY TRANSFER CENTER

Satish C. Tripathi, Ph.D., R.A.C.
Director, Worldwide Regulatory Strategy
PFIZER

Jonathan Wang, Ph.D.
General Manager, China
BURRILL & CO.

Michael Wise
Partner, Chair of China Intellectual Property Practice
PERKINS COIE

Li Yan, Ph.D.
Assistant Director, Hematology & Oncology
CENTOCOR

Dajun Yang, M.D., Ph.D.
Vice President of Research
ASCENTA THERAPEUTICS

Dan Zhang, M.D., M.P.H.
Head Clinical Development & Safety
SIGMA-TAU RESEARCH

Han-Cheng Zhang, Ph.D.
Principal Scientist
JOHNSON & JOHNSON PRD

Zhenping Zhu, Ph.D.
Vice President, Antibody Technology
IMCLONE SYSTEMS
What Is Impact China?
Impact China II is the leading industry gathering for those interested in the Chinese pharmaceutical market. Hundreds of executives from the US, EU, India, China, and Asia Pacific attended our inaugural meeting in Shanghai in September 2005. The conference’s theme is to provide attendees with “on-the-ground” information from the most experienced speakers and to facilitate introductions and networking between Western and Eastern pharmaceutical industry executives.

Who Will Be At Impact China?
At the inaugural Impact China: Shanghai meeting, over 250 attended the meeting representing over 10 different countries. Over 50% of the attendance came from the US & EU.

If you are interested in learning what China has to offer in the following areas, you will greatly benefit from attending this event.

- Global Business Development & Strategic Planning
- Clinical Trials
- Global Sourcing
- Drug Discovery & Development
- Intellectual Property & Patents
- Venture Capital Investors

5 Reasons Why You Should Attend Impact China

1. “On-the-Ground Experiences”: The theme for Impact China II is to provide attendees with knowledge of the Chinese market through case studies by companies and speakers who are “in the trenches.” Our speakers have been encouraged to present what they’ve learned, good or bad, in the current pharmaceutical market in China.

2. Networking, Networking, Networking! Hours of breaks and social activities creates unparalleled networking with hundreds of life science executives from U.S., Europe, China and more.

3. Off-Site Visits: A unique opportunity to attend pre-arranged off-site visits to local pharmaceutical and biotech companies to see what Beijing has to offer. You’ve come this far, why not see what Beijing affords beyond the conference venue.

4. Pre-Conference Workshops: Three distinct and comprehensive workshops to choose from on “Preclinical Requirements for the Start of Clinical Trials in China,” “IP Matters in Cross-Border Technology Transfer,” and “Best Business Practices of Starting a Life Science Company in China.”

5. Specialized Program Agenda: Whether your specialty is in business development, strategic planning, clinical trials, drug discovery/development, global sourcing, or an investor, you can customize your agenda to fit your needs.

Customize Your Program Agenda!
On Tuesday, May 23, we have expanded the agenda into 3 distinct tracks that will allow you to tailor the program according to your interests and specialization.

TRACK A: Conducting Clinical Trials in China
Is your company interested in conducting clinical trials in China? Or are you looking for project management strategies to optimize your current trials ongoing in China? Maybe you’re looking to outsource clinical trials to China. Multinational companies with experience in conducting trials in China will discuss the benefits and current challenges of conducting clinical trials in China.

The Emerging Drug R&D Landscape in China
Drug discovery efforts in China are beginning to bear fruit. Many multinational companies have set up drug discovery centers in China and many Chinese biotechs are now conducting “modern” drug discovery. This session will highlight the tremendous progress and future outlook of the drug discovery landscape in China.

TRACK B: Innovative Drug R&D
We have designed this track specifically for the local Chinese audience. Informative presentations and panel discussions will outline successful strategies in drug discovery and development, FDA regulations for API and Generic Drugs, and conducting clinical trials in the West.

TRACK C: Global Sourcing From China
If you are a purchaser from outside of China or a supplier from China, this track is for you. The numerous outsourcing opportunities and challenges that China offers the industry will be discussed in detail from the regulatory perspective as well as from the purchaser and supplier views. We have organized a nice mix of speakers from multinational, Chinese pharma, and suppliers to quickly update you on sourcing from China.
WORKSHOP #1 — 4:00 - 7:00
Preclinical to Clinical Development: SFDA vs. FDA

The U.S. FDA published a Guidance for Industry in November 1995 for the content and format of Investigational New Drug Applications (IND) for Phase I studies of drugs, including well-characterized, therapeutic, biotechnology-derived products. This Guidance describes in detail the essential elements in an IND submission document. Prior to the IND submission, the Sponsor must request a pre-IND meeting with the FDA to discuss their proposed toxicology and clinical study designs as well as their manufacturing process and drug release criteria. The China SFDA processes and procedures for the commencement of Phase I clinical studies are more stringent. A comparison and contrast of the IND requirements for both countries will be presented.

WORKSHOP LEADERS:
Glenn Rice, Ph.D., CEO and President
BRIDGE PHARMACEUTICALS
Ada Kung, Ph.D., DABT, Senior Vice President
BRIDGE PHARMACEUTICALS
Jo Shen, CEO and President
SCINOPHARM

Session Led By:
ShengQing Peng, Ph.D., Director & Professor
BEIJING NATIONAL DRUG & SAFETY EVALUATION LABORATORY
James Ho, M.D., Ph.D., DABCC, Director, Center for Clinical Laboratory Development
CHINESE ACADEMY OF MEDICAL SCIENCES
Mark Engle, CEO and President
EXCEL PHARMASTUDIES

WORKSHOP #2 — 4:00 - 7:00
IP Matters in Cross-Border Technology Transfer

Despite emerging economic growth in China and its enormous market potential, many US universities and biotech companies have chosen not to pursue patent protection in China because of perceived weak IP protection and enforcement. Biotech and pharmaceutical therapeutics discovered today will reap their fruit in five to ten years when China has evolved into a more mature economy. Is today’s perception of IP protection and enforcement a valid reason to forego IP protection in China? Currently, Chinese companies are searching for new technologies to license from abroad to develop and commercialize in the China market. Meanwhile, foreign companies recognized the research capacity of this emerging country and have licensed technology developed in China. Thus, there is an increasing demand in cross-border transfer of technology between Chinese companies and foreign entities. A panel of experts from the US and China will discuss intellectual property issues involved in cross-border technology transfer, share their experiences in licensing technologies to and from China, and discuss the benefits and challenges of cross-border technology transfer.

WORKSHOP LEADERS:
Michael Wise, Partner, Chair of China Intellectual Property Practice
PERKINS COIE
Steve Ferguson, Ph.D., Director, Division of Technology Development and Transfer
NATIONAL INSTITUTES OF HEALTH (NIH)
Alan Paau, Ph.D., Assistant Vice Chancellor, Director of Office of Technology Transfer
UNIVERSITY OF CALIFORNIA AT SAN DIEGO

Session Led By:
Rongxin Gan, Ph.D., Vice President
SHANGHAI INSTITUTE FOR BIOLOGICAL SCIENCES
CHINESE ACADEMY OF SCIENCES
James J. Zhu, Ph.D., Attorney at Law
PERKINS COIE

WORKSHOP #3 — 4:00 - 7:00
Best Business Practices of Starting a Life Science Company in China

This workshop shares best business practices and operating tactics to assist new China ventures achieve superior economic performance. From an HR perspective, we will review recruiting, training, and retaining a bilingual and bi-cultural team. We will review evolving China-specific HR issues such as heterogeneous workforce management and integration, fringe benefits, customary non-monetary incentives (commuting allowance, lunch meals, subsidized housing for local staff, etc), confidentiality, anti-compete and other HR issues specific for China. From corporate structure perspective, we will review the pros and cons of various possible structures including representative offices, JV’s, and WFOE’s. We will review the total cost of operating a life science company in China, covering specific macro and micro economic data- from salaries, salary appreciation, location specific factors, VAT tax, corporate taxes, incentives, etc.

WORKSHOP LEADERS:
Mark Xu, Director, Global Strategic Business Analysis
BRIDGE PHARMACEUTICALS
Alan Tsui, Asia Pacific M&A Tax Leader and China Global Strategic Clients Tax Leader
DELOITTE & TOUCHE
Richard Zhang, Partner
MCKINSEY CHINA (INVITED)

Session Led By:
Kevin Xiao, Director of HR
PFIZER GLOBAL PHARMACEUTICALS CHINA (INVITED)
Shengming Lu, Ph.D., Director
BEIJING LABORATORY ANIMAL RESEARCH CENTER
Don Williams, Corporate Partner
WILSON SONSINI GOODRICH & ROSATI
MONDAY, MAY 22, 2006

7:00 - 8:00
Registration & Breakfast

8:00 - 8:10
Chairpersons’ Opening Remarks
Glenn Rice, Ph.D., President & Chief Executive Officer
BRIDGE PHARMACEUTICALS
Mark Engel, Chief Executive Officer & President
EXCEL PHARMASTUDIES

MORNING KEYNOTES

8:10 - 8:45
Challenges for Success in China: A Multinational Company’s Experience
Wang Baoping, Ph.D., Director
NOVO NORDISK CHINA

8:45 - 9:20
New Business Models for R&D in the Global Pharmaceutical Industry
Lorenz Ng, M.D., Ph.D., Vice President, Research Alliance & Business Development, Asia Pacific
ELI LILLY ASIA

9:20 - 9:55
Small Molecules for Small Minds: Discovering and Developing Biopharmaceuticals Comes of Age
Steven J. Projan, Ph.D., Vice President & Head Biological Technologies
WYETH RESEARCH

9:55 - 10:25
Mid-Morning Networking Break

10:25-11:00
Several New Ongoing Regulations in China’s Pharmaceutical Industry
Ming-De Yu, Executive Chairman of the Board
CHINA WORLDBEST LIFE INDUSTRY CO.

11:00 - 11:35
How Chinese Pharmas Can Compete Globally
Huacheng Wei, M.B.A., Chairman of the Board
BEIJING PHARMACEUTICAL GROUP CO.

11:35 - 12:10
Start-up Biotech Companies & Global Collaborations in China
Jing Cheng, Ph.D., Chief Executive Officer
CAPITALBIO CORPORATION

12:10 - 1:30
Networking Luncheon

1:30 - 1:55
China Pharmaceutical R&D — A Strategic Choice
Backed by strong government support and increasing MNC interest, China is rising on the global stage of pharmaceutical R&D. The country is rapidly building up scientific capability across the pharmaceutical R&D value chain. This coupled with vast talent pool, improving IPR and regulatory environment are making the China opportunity enticing. However capturing the China R&D opportunity requires thoughtful strategy rather than piecemeal approach. Motives should go beyond the cost factor. The real value of conducting R&D in China is that this is a strategic lever to help global pharmaceutical companies achieve their China ambition.
Rachel Lee, Senior Manager
BOSTON CONSULTING GROUP SHANGHAI

1:55 - 2:20
Commercialization and Marketing in China: What It Takes To Be Successful
Commercialization skills in the Chinese pharmaceutical market are arguably the single most important factor between success and failure, but at the same time it is the most difficult factor to achieve. The market is characterized by 20% plus market growth, 30% rep turnover, and challenges in building depth in management teams. Success therefore, even for the best companies is not guaranteed. This presentation will focus on the key factors that separate the winners from the losers in China, including:
- An overview of the market and the dynamics driving growth
- Key therapy areas and their outlook
- Case studies of successful companies and what has driven their achievements
- Novel approaches on pricing and what the outlook is for pricing
- Strategies for improving representative allocation on high priority hospitals and physicians

2:20 - 2:40
Why Can’t Generic Drugs Capture Their Fair Share Of The Market In China?
In Western countries, generic drugs once marketed, quickly erode the market share of the originator drug. However, in China the originator drug can co-exist or even grow its market share in the face of multiple local generics. This presentation will discuss the healthcare economics and the marketing practices that serve as the underlying reasons for this.
Jack Chen, Biopharmaceuticals Business Unit Director
NOVO NORDISK CHINA

2:40 - 3:00
The Global Regulatory Environment & The Impact of ICH: Challenges & Opportunities for Global Pharmaceutical Companies
International Conference on Harmonization (ICH) is a joint Government-Industry initiative of US, EU and Japan on harmonization of guidance documents, terminology and format and content of various components of regulatory dossier for registration of medical products in these geographies. Asian countries especially China and India are heading in the direction of becoming leading economies of this century. We hope to address: a) How can the Pharmaceutical Industry in these countries reap the benefits of post-ICH era that has resulted in better partnership between the regulators and the regulated industry in US, EU and Japan? b) In what ways should regulatory environment in Asian countries change to better facilitate partnership between pharmaceutical industry in these nations and three regions of ICH? c) How can China and India benefit from their strengths in becoming pharmaceutical leaders? The objective of this presentation is to introduce the dynamics of ICH process and outcomes; follow up efforts in ASEAN (Association of Southeast Asian Nations) nations; and the opportunities that ICH has provided for speedier registration of pharmaceuticals and biotechnology products in major economies.
Satish C. Tripathi, Ph.D., R.A.C., Director, Worldwide Regulatory Strategy
PFIZER

2:20 - 2:40
Why Can’t Generic Drugs Capture Their Fair Share Of The Market In China?
In Western countries, generic drugs once marketed, quickly erode the market share of the originator drug. However, in China the originator drug can co-exist or even grow its market share in the face of multiple local generics. This presentation will discuss the healthcare economics and the marketing practices that serve as the underlying reasons for this.
Jack Chen, Biopharmaceuticals Business Unit Director
NOVO NORDISK CHINA

2:40 - 3:00
The Global Regulatory Environment & The Impact of ICH: Challenges & Opportunities for Global Pharmaceutical Companies
International Conference on Harmonization (ICH) is a joint Government-Industry initiative of US, EU and Japan on harmonization of guidance documents, terminology and format and content of various components of regulatory dossier for registration of medical products in these geographies. Asian countries especially China and India are heading in the direction of becoming leading economies of this century. We hope to address: a) How can the Pharmaceutical Industry in these countries reap the benefits of post-ICH era that has resulted in better partnership between the regulators and the regulated industry in US, EU and Japan? b) In what ways should regulatory environment in Asian countries change to better facilitate partnership between pharmaceutical industry in these nations and three regions of ICH? c) How can China and India benefit from their strengths in becoming pharmaceutical leaders? The objective of this presentation is to introduce the dynamics of ICH process and outcomes; follow up efforts in ASEAN (Association of Southeast Asian Nations) nations; and the opportunities that ICH has provided for speedier registration of pharmaceuticals and biotechnology products in major economies.
Satish C. Tripathi, Ph.D., R.A.C., Director, Worldwide Regulatory Strategy
PFIZER

3:00 - 3:30
Mid-Afternoon Networking Break
TUESDAY, MAY 23, 2006 – TRACK A: CLINICAL TRIALS/R&D IN CHINA

8:00 - 8:05
Chairpersons’ Opening Remarks

Dan Zhang, M.D., M.P.H., Head, Clinical Development & Safety
SIGMA-TAU RESEARCH

Jay Mei, M.D., Ph.D., Associate Director, Clinical Research
Global Development

JOHNSON & JOHNSON PRD

8:05 - 8:40
Drug Registration in China
STATE FOOD & DRUG ADMINISTRATION (INVITED)

8:40 - 9:10
Clinical Trials in China — Expectations from Global Companies

More and more multinational pharmaceutical companies have increased their investment in China either targeting the future Chinese market and/or contributing to global drug development by including China in global studies. Surveys have shown that the pharmaceutical industry is more reluctant than other industries to invest in China due to some concerns. One area that needs to be improved is the clinical trials infrastructure. This session will discuss the expectations from multinational pharmaceutical companies about clinical trial in China.

Ruiping Dong, M.D., Ph.D., Vice President, Research & Development
BRISTOL-MYERS SQUIBB JAPAN

9:10 - 9:40
Outsourcing Clinical Trials in China — Trends and Opportunities

This session will discuss: (1) a brief overview of the drivers for growth of number of trials being done in China with a focus on where these trends are likely to lead; and (2) different ways in which both large pharma and smaller international biotechs are taking advantage of the current China clinical trial environment.

Mark Engel, Chief Executive Officer & President
EXCEL PHARMASTUDIES

9:40 - 10:10
Mid-Morning Networking Break

10:10 - 10:40
Opportunities and Challenges for Multinational Companies to Conduct Global Studies in China

Multi-national companies (MNCs) have been doing global clinical studies in China for several years. A long regulatory timeline for Clinical Trial Approval (CTA) remains to be a major issue. It therefore requires MNCs to bear good internal planning and supporting processes for early CTA submission and SFDA evaluation. A successful technical evaluation meeting requested by the Center for Drug Evaluation for NMEs is critical to ensure CTA being issued timely and with minimum impact on the clinical program. The local clinical team needs to prepare early in advance to enable clinical trial initiation as soon as the CTA is received. This includes preparations of investigators sites, electronic data transfer, central lab, trial supply and others.

Rong (Rose) Qiu, M.D., Medical Director
JANSSEN CHINA

10:40 - 11:10
China Clinical Trial Strategies for Biotech and Small Pharma

Clinical development is a lengthy and costly process. Interested in clinical trials in China, but think your company is too small? The ability to capitalize on the strengths of China and its booming pharmaceutical industry are not limited to the industry’s major organizations. With a large naive patient population, talented medical professionals, and favorable cost structure, biotech and small pharma can gain real strategic value in their drug development process. Additional revenue opportunities may exist by completing market registration and partnering with a China pharmaceutical company. This discussion is dedicated to helping clarify the market’s true appeal and potential for smaller organizations through the review of benefits, challenges, obstacles, and solutions surrounding China.

Ken Ren, President
ACCELOVANCE CHINA

11:10 - 12:10 PANEL DISCUSSION
Planning & Management of Global Clinical Trials with Enrollment in China

Clinical development is a lengthy and costly process. Reducing development time and cost, while maintaining the quality of data, is a constant challenge for drug developers. Conducting trials globally for certain indications becomes a necessity rather than an option. There is a notion that conducting clinical trials in China will reduce the cost. How about the time to the FPI (first patient in) and LPO (last patient out) and quality of data? Is it possible to conduct a pivotal study in China alone? What are the regulatory hurdles
you will be faced with? What is the impact of Chinese culture on your clinical development planning when involving sites from China? If you have these or other related questions, please join us to have an in-depth discussion with our speakers.

**DISCUSSION LEADER:**
Dan Zhang, M.D., M.P.H., Head, Clinical Development & Safety
SIGMA-TAU RESEARCH

**PANELISTS:**
Ling Su, Ph.D., Director, Medical & International Pharma Development
SHANGHAI ROCHE PHARMACEUTICALS
Rong (Rose) Qiu, M.D., Medical Director
JANSSEN CHINA
Ruiping Dong, M.D., Ph.D., Vice President, Research & Development
BRISTOL-MYERS SQUIBB JAPAN

**12:10 - 1:45**
Networking Luncheon

**1:45 - 2:15**
Clinical Trials and Patient Care Experience with Novel Oncology/Hematology Drugs
Fang Ping Chen, M.D., Director of Hematology Department, President
XIANG-YA MEDICAL COLLEGE/ XIANG-YA HOSPITAL

**THE EMERGING DRUG R&D LANDSCAPE IN CHINA**

**SESSION LEADER:**
Chair’s Opening Remarks
Li Chen, Ph.D., Head of Research, CSO
 ROCHE R&D CHINA

**2:15 - 2:45**
Drug Discovery in China: Emerging Landscape of Innovation
Drug discovery, a concept that was imposed on Chinese biotech and pharma industry after China entered into WTO, is now starting to bear fruit. Creation of this emerging landscape in China has many reasons. In my presentation, I’ll discuss our understanding of the drug discovery environment in China and future perspectives of discovery innovation.
Li Chen, Ph.D., Head of Research, CSO
 ROCHE R&D CHINA

**2:45 - 3:15**
Making China Your Company’s Friend
Ting Lei, Ph.D., Director
BEIJING PHARMA & BIOTECH CENTER

**3:15 - 3:45**
Mid-Afternoon Networking Break

**3:45 - 4:15**
The Role of China-Based Operations in Drug Discovery and Development
Guoxin Zhu, Ph.D., Chief Scientific Officer
LILLY CHINA R&D

**4:15 - 4:45**
Can Chinese Biotechs Offer Modern Drug Discovery?
China is emerging as the fifth largest pharmaceuticals marketplace by 2010. China also offers great advantages for cost effectiveness of early stage proprietary drug discovery and preclinical with over-all operation of highly talented and skilled scientists while gaining good track records in biomedical and clinic research. With continuing improvement in IP issues and harmonization of regulatory process, China can be an ideal place for outsourcing drug discovery, licensing in/out, and investment in biotech arena. This presentation will discuss Chipscreen Biosciences’ experiences as the leading drug discovery in China and its role in the global pharmaceutical arena.
Xian-Ping Lu, Ph.D., Co-Founder & Chief Scientific Officer
CHIPSCREEN BIOSCIENCES

**4:45 - 5:15**
Building the Translational Highway from Bench to Clinic in China
Ling Chen, M.D., Ph.D., Director General & Professor
GUANGZHOU INSTITUTE OF BIOMEDICINE & HEALTH

**5:30 - 8:00**
Off-Site Cocktail Reception
Bridge Pharmaceuticals and Capital BioChip will host a special cocktail reception for Impact China attendees in ZhongGuanCun Life Science Park.

**8:00 - 8:30**
Chairpersons’ Opening Remarks
Huimin Chen, Ph.D., Senior Research Scientist
WYETH RESEARCH
Zhi Hong, Ph.D., Vice President of Drug Discovery
VALEANT PHARMACEUTICALS
Dajun Yang, Ph.D., Vice President of Research
ASCENTA THERAPEUTICS
Han-Cheng Zhang, Ph.D., Principal Scientist
JOHNSON & JOHNSON PRD

**8:30-9:40 PANEL DISCUSSION**
Development of Antibody-Based Therapeutics in China
Antibody-based therapeutics has garnered considerable interest from Chinese pharmaceutical and biotech companies. This exciting panel of experts will provide the audience with an overview of antibody development with regards to China and highlight the current challenges Chinese researchers are facing. A case study on intellectual property will also be presented.

**MODERATOR:**
Zhenping Zhu, Ph.D. Vice President, Antibody Technology
IMCLONE SYSTEMS INC.

**PANELISTS:**
Yajun Guo, Ph.D., Professor, Director
SHANGHAI ANTIBODY & CELL ENGINEERING CENTER
Zhinan Chen, Ph.D., Professor, Director
CELL ENGINEERING RESEARCH CENTER XI’AN, CHINA
Tony Chen, Attorney at Law
PAUL HASTINGS

**9:40 - 10:10**
Mid-Morning Networking Break
Innovative Drug R&D is a resource-intensive process that requires not only innovation but also patience and commitment. Can China leverage its advantageous development capability to support and expand its domestic pharmaceutical industry? What are the future challenges and opportunities faced by Chinese pharmaceutical companies? The Round Table discussion will focus on the following issues related to R&D:

- Selecting Therapeutic Indications and Disease Targets
- Establishing R & D Strategies - Target Product Profiles
- Building a Best-in-Class R & D Team
- Managing Intellectual Properties
- Regulatory and Business Development Strategies

**MODERATOR:**
Zhi Hong, Ph.D., Vice President of Drug Discovery

**VALEANT PHARMACEUTICALS**

**PANELISTS:**
Huimin Chen, Ph.D., Senior Research Scientist
WYETH RESEARCH
Dajun Yang, Ph.D., Vice President of Research
ASCENTA PHARMACEUTICALS
Jun Bao, Ph.D., Associate Director of Business Development
ICOS CORPORATION
Shelly Xiong, Director of China Operations
COVANCE
Michael Z. Wang, Ph.D., Senior Scientist, Biology
GILEAD SCIENCES

**10:10 - 10:30**

Networking Luncheon

**10:30 - 11:30**

**10:10 - 12:10 ROUNDTABLE DISCUSSION**

Innovative Drug R&D II

In a continuation of the morning’s discussion, hear from a panel of global experts in drug discovery and development, addressing the latest, most innovative topics in Drug R&D. This discussion will delve deeper into scientific topics of interest. The audience is encouraged to bring questions for the panelists.

**MODERATORS:**
Han-Cheng Zhang, Ph.D., Principal Scientist
JOHNSON & JOHNSON PRD
Huimin Chen, Ph.D., Senior Research Scientist
WYETH RESEARCH
Zhi Hong, Ph.D., Vice President of Drug Discovery
VALEANT PHARMACEUTICALS

**PANELISTS:**

**ASCENTA PHARMACEUTICALS**
Dajun Yang, Ph.D., Vice President of Research
Lixin Zhang, Ph.D., President
SYNERZ PHARMACEUTICALS
Guzhong Rui, Ph.D., Director
CHINESE RESEARCH & COMMERCIALIZATION CENTER
Zeqi Zhou, Ph.D., Vice President, Chief Scientific Officer & Chief Operating Officer
EGENIX
Michael Z. Wang, Ph.D., Senior Scientist, Biology
GILEAD SCIENCES
Zhenping Zhu, Ph.D. Vice President, Antibody Technology
IMCLONE SYSTEMS INC.

**10:10 - 12:10 ROUNDTABLE DISCUSSION**

Innovative Drug R&D

Pharmaceutical R&D is a resource-intensive process. Many companies have utilized this approach to achieve commercial success. Increasingly US-based companies have stepped up their licensing efforts in Asian regions. What are the elements of success in R&D partnership? How can Chinese Healthcare Companies best attract Western partners?

**MODERATOR:**
Zhi Hong, Ph.D., Vice President of Drug Discovery

**VALEANT PHARMACEUTICALS**

**PANELISTS:**
Huimin Chen, Ph.D., Senior Research Scientist
WYETH RESEARCH
Dajun Yang, Ph.D., Vice President of Research
ASCENTA PHARMACEUTICALS
Jun Bao, Ph.D., Associate Director of Business Development
ICOS CORPORATION
Shelly Xiong, Director of China Operations
COVANCE
Michael Z. Wang, Ph.D., Senior Scientist, Biology
GILEAD SCIENCES

**12:10 - 1:45**

Networking Luncheon

**1:45 - 2:50 ROUNDTABLE DISCUSSION**

Innovative Drug R&D II

Pharmaceutical R&D is a long and capital intensive process. Many companies have utilized this approach to achieve commercial success. Increasingly US-based companies have stepped up their licensing efforts in Asian regions. What are the elements of success in R&D partnership? How can Chinese Healthcare Companies best attract Western partners?

**MODERATOR:**
Han-Cheng Zhang, Ph.D., Principal Scientist
JOHNSON & JOHNSON PRD
Huimin Chen, Ph.D., Senior Research Scientist
WYETH RESEARCH
Zhi Hong, Ph.D., Vice President of Drug Discovery
VALEANT PHARMACEUTICALS

**1:45 - 2:50 ROUNDTABLE DISCUSSION**

Innovative Drug R&D

Pharmaceutical R&D is a long and capital intensive process. Many companies have utilized this approach to achieve commercial success. Increasingly US-based companies have stepped up their licensing efforts in Asian regions. What are the elements of success in R&D partnership? How can Chinese Healthcare Companies best attract Western partners?

**MODERATOR:**
Zhi Hong, Ph.D., Vice President of Drug Discovery

**VALEANT PHARMACEUTICALS**

**PANELISTS:**
Huimin Chen, Ph.D., Senior Research Scientist
WYETH RESEARCH
Dajun Yang, Ph.D., Vice President of Research
ASCENTA PHARMACEUTICALS
Jun Bao, Ph.D., Associate Director of Business Development
ICOS CORPORATION
Shelly Xiong, Director of China Operations
COVANCE
Michael Z. Wang, Ph.D., Senior Scientist, Biology
GILEAD SCIENCES

**2:50 - 3:15**

Success Through R&D Partnerships

Success Through R&D Partnerships

**MODERATOR:**
Zhi Hong, Ph.D., Vice President of Drug Discovery

**VALEANT PHARMACEUTICALS**

**PANELISTS:**
Huimin Chen, Ph.D., Senior Research Scientist
WYETH RESEARCH
Dajun Yang, Ph.D., Vice President of Research
ASCENTA PHARMACEUTICALS
Jun Bao, Ph.D., Associate Director of Business Development
ICOS CORPORATION
Shelly Xiong, Director of China Operations
COVANCE
Michael Z. Wang, Ph.D., Senior Scientist, Biology
GILEAD SCIENCES

**3:15 - 3:45**

Mid-Afternoon Networking Break

**3:45 - 4:15**

Conducting Clinical Trials in the US

Conducting clinical trials with the US population is a necessary part of the NDA application process for most pharmaceutical/biotech products, regardless of where they are produced. Compared with clinical studies done in China, there are many major differences in clinical operations in the US, including pre-IND & IND filing processes, IRB and/or Scientific Committee review, liabilities in clinical studies, safety handling, and cost/timeline in patient enrollment, etc. This presentation will highlight these differences for those companies who are relatively new to the US market.

**MODERATOR:**
Dan Zhang, M.D., M.P.H., Head, Clinical Development & Safety
SIGMA-TAU RESEARCH

**4:15 - 4:45**

US and EU GMPs: Their Interaction with the ICH and Pharmacopeias

US and EU GMPs: Their Interaction with the ICH and Pharmacopeias

This presentation will help the participant to understand the interrelationships among the U.S. and E.U. GMPs, ICH guidance documents, the USP, and the EP. The talk will cover the use of the pharmacopeias to set specifications and testing methods, and the use of guidance documents and other advisory documents to develop procedures to comply with the GMPs.

**MODERATOR:**
Steven S. Kuwahara, Ph.D., President
GXP BIOTECHNOLOGY

**4:45 - 5:15**

Strategies of Generic Pharmaceuticals

Strategies of Generic Pharmaceuticals

**MODERATOR:**
Lijuan Tang, Ph.D., Senior Research Scientist, Formulation Development
ALPHARMA

**5:30 - 8:00**

Off-Site Cocktail Reception

Bridge Pharmaceuticals and Capital BioChip will host a special cocktail reception for Impact China attendees in ZhongGuanCun Life Science Park.
Regulatory Requirements in Outsourcing Research to China and Importing Active Pharmaceutical Ingredients to the U.S.

Mr. Chen will present an overview of the regulation of drugs and medical devices in the U.S. and China, and focus his discussion on the regulatory requirements of the U.S. FDA and China SFDA in two areas that present many opportunities for U.S.-China life sciences companies: (1) outsourcing preclinical research and clinical trials from the U.S. to China, and (2) importing active pharmaceutical ingredients from China to the U.S.

Steven S. Kuwahara, Ph.D., President
GXP BIOTECHNOLOGY

Global Outsourcing of the Manufacturing of Pharmaceutical Ingredients: Needs of the Supplier & Purchaser

This talk will focus on the requirements that a purchaser needs to impose on its supplier. In most cases, these arise from the requirements imposed on the purchaser by regulatory bodies. The best relationships develop when the supplier is prepared to meet the needs of the purchaser and the recipient is careful to define their needs. In addition to the requirements imposed by Q7A, needs imposed by documents such as Drug Master Files (DMFs), Clinical Investigation protocols, GLPs, and Quality Agreements will be discussed. Several well-known examples of problems caused by suppliers will be presented and solutions to them will be discussed.

Steven S. Kuwahara, Ph.D., President
GXP BIOTECHNOLOGY

Sourcing From Emerging Markets

Pharmaceutical companies and their suppliers are facing many pressures in the competitive world environment. Emerging markets in the fine chemical area offer a wide variety of benefits to pharma companies around the world. Certainly, lower cost of materials is an attraction for supply chains. However, key to the success of fine chemical sourcing is to identify quality manufacturers that have outstanding technical competence, high adherence to ethical business practices, effective communications with customers, and maintain compliance in the safety, health and environment areas as well as cGMP. The evaluation of fine chemical, intermediate and API manufacturers against those key business areas will be discussed.

Robert B. Miller, Ph.D., Program Manager, Global Process R&D
ABBOTT LABORATORIES

Shopping in the Global Technology Marketplace

Technology transfer has become an important activity between the inventors and the industries. The researchers are the inventors of many innovative technologies! It is important for all the scientists now to understand and realize that their talents and achievements can be much more valuable if they actively communicate with the industrial partners. This presentation gives a brief introduction of Roche & its divisions, research focus & interest, and step-by-step procedures for collaboration set-up and technology evaluation and transfer.

Qiming Sun, Regional Manager of Far East, Applied Science
ROCHE DIAGNOSTICS

Opportunities in Global Chemical Pharmaceutical Manufacturing

The new global trend in chemical pharmaceutical outsourcing
The opportunities and challenges for Chinese chemical pharmaceutical industries
Strategies vs. execution
Conclusions

Frances Hu, Vice President, Zhenshen Import & Export Co.
SHANGHAI PHARMACEUTICAL GROUP
Defining and Achieving Innovation in 21st Century Medicine

Today the pharmaceutical industry is faced with higher investments in R&D that appear to be driving lower than anticipated returns. In my presentation I will first address the myths and realities that lead to this conclusion. The realities include our recent focus on complex, polygenic diseases with unmet needs, the impact of mergers and acquisitions, and perhaps too great a focus on developing “me too” types of medicines. While there are no simple answers, it is clear that our investments during the last decade have created a solid foundation that will and are allowing us to discover differentiated medicines that address complex diseases such as type 2 diabetes, cardiovascular disease and arthritis, to name a few. I will provide several examples that demonstrate that we are changing the myths associated with Pharmaceutical R&D productivity and innovation into the reality of discovering important medical breakthroughs. Central to this is our recent creation of the Roche R&D Center in Shanghai, which represents our major long-term commitment to China and reinforces the importance of China as a global player in the field of biomedical science and a growing market for our healthcare products.

Lee E. Babiss, Ph.D., Vice President, Preclinical R&D
Hoffman-La Roche
The conference agenda reflects the most up-to-date version of the program at the time of printing. Please note that the speakers and topics in the agenda are subject to change prior to the conference date. The most current program including any changes made to the schedule can be found at www.srinstitute.com/china.
May 23, 2006
Bridge Pharmaceuticals State-of-the-Art Research Facility
Join us for a special cocktail reception off-site hosted by Bridge Pharmaceuticals at its recently opened 78,000 sq. ft. facility in ZhongGuanCun Life Science Park. The entire project was designed and built for US level AAALAC and GLP certification from the ground up. This facility was completed November 2005 and dedicated by San Francisco Mayor Gavin Newsom and Beijing Vice Mayor Zhang Mao.

Capitol BioChip Corporation
CapitalBio and its affiliated National Engineering Research Center for Beijing Biochip Technology are housed in a 260,000 square feet facility in the ZhongGuanCun Life Science Park, the home to a number of life science and innovative pharmaceutical companies in Beijing, China. CapitalBio and the center have attracted many world-class scientists and specialists from the U.S. and Europe, among their more than 300 staff. With three subsidiary and portfolio companies, AVIVA Biosciences in San Diego, California, Chipscreen Biosciences in Shenzhen and Wandong Medical Equipment Co. in Beijing, CapitalBio has developed cutting-edge and integrated platform technologies for Biochips, Bioautomation and Biomaterials.

May 25, 2006
ZhongGuanCun Life Science Park:
Zhong-Guan-Cun(ZGC) Life Science Park is a professional science park developed by the Beijing Municipal Government with the purpose of developing the knowledge-based economy in the capital area. As an important part of ZGC Science and Technology Park system, ZGC Life Science Park aims at building an international-level first class science and technology park and will be developed into an international high-tech park that integrates R&D, enterprises’ incubating, mid-testing and producing, results’ transferring, venture capital, international communication and talents’ training.

Registration for this exclusive site-visit will be limited to 30 participants. Please contact the organizer, Jon Liong at jliong@srintstitute.com. Register early to secure your spot!

ITINERARY:
8:30-9:30
Welcome To Zhong-Guan-Cun Life Science Park
• The brief introduction of bio-medical industry of Beijing
• General situations such as some economic indicators and statistic data
• Preferential policies for investment
• R&D capability
• Clinical resources
• Human resources
• Costs
• The introduction of Zhong-Guan-Cun Life Science Park
• Geographical location
• Master plan
• Basic facilities
• Related technological supporting system
• Brief introduction of companies based in Zhong-Guan-Cun Life Science Park
• Some preferential policies for investing in the Park

9:30-10:20
A Foreign Company Based in Zhong-Guan-Cun Life Science Park
Bridge Pharmaceuticals, Inc. (Vital Bridge) a US-headquartered company focused on US-level GLP drug development resources for US, EU and Asia clients. Bridge has a large state-of-the-art drug development facility in the heart of ZhongGuanCun that achieves US level toxicology, pharmacology and safety pharmacology services for worldwide regulatory IND filings.

10:20-11:10
A Company Specialized in Basic Research
• To introduce the capability of basic research in Beijing
• General introduction
• Their specialization and capability
National Institute of Biological Sciences, Beijing, contains 30 laboratories of international level. The appointment of Director of NIBS is made following a rigorous international search process. In 2003, Dr. Xiaodong Wang, a member of the U.S. National Academy of Sciences and a biochemist and cell biologist from the University of Texas Southwestern Medical Center, was appointed to the director of NIBS.

OFF-SITE VISITS
We have arranged off-site visits to local company sites in the prestigious ZhongGuanCun Life Science Park. This presents attendees with a wonderful opportunity to see firsthand the facilities local to Beijing.
## IMPACT CHINA II: SCHEDULE AT-A-GLANCE

**Sunday, May 21, 2006**
1:00-3:00  Exhibitor Set-Up Begins  
3:00-4:00  Pre-Conference & Workshop Registration  
4:00-7:00  Pre-Conference Workshops  
7:00-8:30  Welcome to Beijing Reception

**Monday, May 22, 2006**
<table>
<thead>
<tr>
<th>Time</th>
<th>Track A: CLINICAL TRIALS/R&amp;D IN CHINA</th>
<th>Track B: INNOVATIVE DRUG R&amp;D</th>
<th>Track C: GLOBAL SOURCING FROM CHINA</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00-8:00</td>
<td>Breakfast &amp; Networking</td>
<td>7:00-8:00</td>
<td>Breakfast &amp; Networking</td>
</tr>
<tr>
<td>8:00-8:10</td>
<td>Chairpersons’ Opening Remarks</td>
<td>8:00-8:10</td>
<td>Chairpersons’ Opening Remarks</td>
</tr>
<tr>
<td>8:10-9:55</td>
<td>Clinical Trials in China</td>
<td>8:10-9:40</td>
<td>Innovative Drug R&amp;D for Chinese Companies</td>
</tr>
<tr>
<td>9:40-10:10</td>
<td>Morning Keynotes</td>
<td>10:10-12:10</td>
<td>Mid-Morning Networking Break</td>
</tr>
<tr>
<td>10:10-12:10</td>
<td>Clinical Trials in China</td>
<td>10:10-12:10</td>
<td>Innovative Drug R&amp;D for Chinese Companies</td>
</tr>
<tr>
<td>12:10-1:40</td>
<td>Networking Luncheon</td>
<td>12:10-1:30</td>
<td>Networking Luncheon</td>
</tr>
<tr>
<td>3:15-3:45</td>
<td>Mid-Afternoon Networking Break</td>
<td>3:15-3:45</td>
<td>Mid-Afternoon Networking Break</td>
</tr>
<tr>
<td>3:45-5:15</td>
<td>The Emerging R&amp;D Landscape in China</td>
<td>3:45-5:15</td>
<td>Clinical Trials/Generics/GMPs for Chinese Companies</td>
</tr>
<tr>
<td>5:30-8:00</td>
<td>Off-Site Cocktail Reception</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Tuesday, May 23, 2006**

**Wednesday, May 24, 2006**
7:00-8:00  Registration & Breakfast  
8:00-8:10  Chairpersons’ Opening Remarks  
8:10-9:40  Morning Keynotes  
9:40-10:10  Mid-Morning Networking Break  
10:10-12:30  Investment in China’s Life Sciences Industry  
12:30-1:30  Networking Luncheon  
1:30-2:45  China vs. The Rest of Pacific Asia  
2:45-4:00  Business Development & Partnerships in Pacific Asia  
4:00  Conference Concludes

**Thursday, May 25, 2006**
8:00-12:00  Off-Site Visits (Please see opposite page for details)
BRIDGE PHARMACEUTICALS is a US-headquartered (Menlo Park, CA) CRO focused on providing dramatically lower cost, FDA compliant preclinical drug development services in Asia (Taiwan and PRC) for US and EU based clients. Bridge was founded by SRI International (formally Stanford Research Institute), which has had a long track record of preclinical drug development success with the FDA. Bridge’s current capabilities include nearly all aspects of preclinical discovery and development, with a particular focus on toxicology, pharmacology, ADME and safety pharmacology. Bridge also provides regulatory services for IND compilation and submission, as well as pre-IND meetings with the FDA.

APEX INTERNATIONAL is one of the largest Contract Research Organizations based in Asia Pacific that offers full range services in clinical drug development. We have operations in Taiwan, China, Korea, Hong Kong, Singapore, Malaysia, Thailand, Philippines and Australia. Our pan-Asia presence enables sponsors to grasp all necessary information and quality services in conducting trials in Asia. APEX’s dedicated team of well trained clinical research professionals in the areas of Global Project Management, Regulatory Services, Site Management, Clinical Monitoring, Data Management, Statistical Analysis, and Medical Writings. Working for clients worldwide, APEX applies its expertise in clinical research and offers the best possible solutions and valuable insights into the clinical and commercial potential of new products. APEX today is a team with over 160 employees that continue to provide expertise services in all aspects of clinical drug development. Our experienced therapeutic areas include oncology, infectious diseases, immunology, cardiology, endocrinology, gastrointestinal, oncology, hematology, psychiatrics and medical device.

EXCEL PHARMASTUDIES (www.excel-china.com) is the leading full service clinical research organization in China. Our main office is in Beijing and we have branch operations in six other large cities (Shanghai, Guangzhou, Chengdu, Nanjing, Shenyang). In the last two plus years, Excel has been involved in about 90 phase I to IV trials in 25 cities at about 130 hospitals, and including about 19,000 patients. The trials have been for either purposes of local registrations or for international approvals. Excel has strong medical, regulatory and data management teams. Our clients include many of the top 50 international pharmaceutical companies and many of the leading Chinese pharmaceutical companies.

BRIDGE PHARMACEUTICALS

PERKINS COIE serves great companies with more than 600 attorneys in 14 offices across the United States and in China. The firm represents clients that range in size from Fortune 100 companies to startups and has historically represented market leaders in traditional and cutting-edge technology industries.

ACCELOVANCE China is a full service CRO focused on conducting high quality Phase 1-IV studies for global and local submission. The company provides strategic options including: patient recruitment campaigns for trials with difficult to enroll indications; study coordinator support or training; proof-of-concept trials; and partnership recruitment for trials with difficult to enroll indications. The company provides strategic options including: patient recruitment campaigns for trials with difficult to enroll indications; study coordinator support or training; proof-of-concept trials; and partnership recruitment for trials with difficult to enroll indications.

MARKEN is a wholly owned subsidiary of Exel plc, the global leader in supply chain management, offering global time sensitive delivery solutions to its customers worldwide. With 130 locations in 120 countries we offer an unparalleled network capability. Marken over the years has offered transport services to many pharmaceutical and biotechnology companies along with the most important CRO’s and central laboratories. We handle and transport biological samples during all phases of clinical trials whether they be infectious or non-infectious, ambient or on dry ice. A number of the services we provide for the pharmaceutical industry include clinical supply and investigative drug shipping, clinical trial co-ordination, recommendation and furnishing of packaging materials, ongoing site support and provision and replenishment of dry ice on a global basis.

BRIDGE PHARMA AND BIOTECH CENTER (BPBC) is one of China’s leading professional consulting agencies in the pharma and biotech field. Its business model can best be described as a non-profit organization (NPO) with the aim of strengthening the innovation of the pharmaceutical and biotechnology industry in Beijing and China. The function of BPBC is to act as the pivot of the Beijing pharma and biotech industry, which is composed of government agencies, research institutions, well-known universities, biomedical enterprises and academic organizations. It also builds the bridge between the industry and outside, including overseas industries, foreign scholars, overseas Chinese professors and students, and domestic industries.

ACCELOVANCE

ACCELOVANCE (Accelerate Drug Discovery and Development) is one of China’s leading professional consulting agencies in the pharma and biotech field. Its business model can best be described as a non-profit organization (NPO) with the aim of strengthening the innovation of the pharmaceutical and biotechnology industry in Beijing and China. The function of BPBC is to act as the pivot of the Beijing pharma and biotech industry, which is composed of government agencies, research institutions, well-known universities, biomedical enterprises and academic organizations. It also builds the bridge between the industry and outside, including overseas industries, foreign scholars, overseas Chinese professors and students, and domestic industries.

BEIJING PHARMA AND BIOTECH CENTER (BPBC) is one of China’s leading professional consulting agencies in the pharma and biotech field. Its business model can best be described as a non-profit organization (NPO) with the aim of strengthening the innovation of the pharmaceutical and biotechnology industry in Beijing and China. The function of BPBC is to act as the pivot of the Beijing pharma and biotech industry, which is composed of government agencies, research institutions, well-known universities, biomedical enterprises and academic organizations. It also builds the bridge between the industry and outside, including overseas industries, foreign scholars, overseas Chinese professors and students, and domestic industries.

BEIJING PHARMA AND BIOTECH CENTER

FORTUNE 100 companies to startups and has historically represented market leaders in traditional and cutting-edge technology industries.

SINO-AMERICAN PHARMACEUTICAL ASSOCIATION (SAPA) Founded in 1993, the Sino-American Pharmaceutical Professionals Association (SAPA) grew rapidly and has become one of the most active and well-recognized Chinese-heritage enduring professional organizations in the United States. SAPA is an independent, nonprofit organization with a membership base of more than 3,000 in more than 35 states in USA, China, Hong Kong, Taiwan and Japan united by a commitment to promoting pharmaceutical science and technology and their essential roles in fostering member’s career development. In service to science, SAPA facilitates communication among scientists, policy makers, government officers, educators, and journalists from both the United States and China through its interdisciplinary conferences, symposia, section meetings, seminars, workshops and diverse publications.

CHINESE BIOPHARMACEUTICAL ASSOCIATION (CBA) is a non-profit organization of professionals in the areas of bio-pharmaceutical research and technology development. It was established in the Spring of 1995 with its headquarters located in the State of Maryland adjacent to the U.S. capital city, Washington D.C. The majority of CBA members are Chinese scientists, researchers, or professors working in government agencies, universities, research institutes, and biotechnology and pharmaceutical industries. Among them, many are doing pioneering research with the National Institutes of Health (NIH), and some are directly involved in the government regulatory process as officers of the Food and Drug Administration. CBA’s Executive Committee consists of research, regulatory and management professionals representing all sectors of the bio-pharmaceutical research and development institutions as well as regulatory agencies. These committee members have volunteered to contribute their time and skills to the founding and development of CBA.

EXCEL PHARMASTUDIES

Sponsors and exhibitors will benefit from Impact China by:
• Networking face-to-face with hundreds of the decision makers from the pharmaceutical and biotechnology industries. These companies are showing the greatest interest in the Chinese & Asian Pacific markets
• Increasing your company’s visibility and reputation on the international level
• Displaying your latest technology platforms & services to an extremely targeted group of attendees
• Building new client relationships and maintaining old ones

For more information on how your company can participate at Impact China, please contact the organizer, Jon E. Liong by phone at (212)967-0095, extension 243 or by email at jliong@srinstitute.com.

The expected attendance at Impact China is 250+ senior level decision makers from multinational pharma and biotech companies as well as companies located in China. They are in charge of their company’s planning, management, outsourcing, investing, intellectual property, and business development in China and the Asia Pacific region.

We have a variety of sponsorship and exhibition opportunities available that are specifically designed to increase your company’s visibility in the market, introduce you to hundreds of potential new clients, and strengthen your relationships with current ones. The benefits of sponsorship and exhibition at Impact China are reaped before, during, and even after the event has concluded.

SPONSORSHIP & EXHIBITION OPPORTUNITIES
THANK YOU TO OUR SUPPORTING ORGANIZATIONS & MEDIA PARTNERS

PAYMENTS: The registration fee for the CONFERENCE ONLY is $1395 on or before March 31, 2006; $1695 thereafter. The registration fee for the CONFERENCE + WORKSHOP is $1595 on or before March 31; $1895 thereafter. Academics may register at $895 (includes pre-conference workshop). This includes breakfasts, lunches, refreshments, receptions, and the conference documentation workbook. Payments may be made by check, American Express, Visa, MasterCard, Discover, or Diner’s Club. Please make checks payable to Strategic Research Institute, L.P. and be sure to write the registrant’s names on the face of the check along with the conference code CS370. PAYMENTS MUST BE RECEIVED BY MAY 1, 2006. CREDIT CARD PAYMENTS MUST ALSO BE RECEIVED BY MAY 1, 2006 TO GUARANTEE YOUR PLACE AT THIS EVENT.

EASY WAYS TO REGISTER

DISCOUNTS

University, hospital, and government employees may register at $895 (includes pre-conference workshop). Industry delegates may register at $300 off the regular conference rate on or before March 31, 2006. Group discounts available for groups of 3 or more; please contact Jon E. Liong at jliong@srinstitute.com for more information.

CANCELLATIONS: All cancellations will be subject to a $250 administration fee. In order to receive a prompt refund, your notice must be received in writing (by letter or fax) BY MAY 1, 2006. We regret refunds will not be issued after this date. The registration may be transferred to you or another member of your organization for any Strategic Research Institute conference during the next 12 months. If you plan to send a substitute in your place, please notify us as soon as possible so that material and preparations can be made. In the event of a conference cancellation, Strategic Research Institute assumes no liability for non-refundable transportation costs, hotel accommodations or additional costs incurred by registrants.

VENUE INFORMATION: Shangri-La Hotel Beijing 29 Zizhuyuan Road Beijing 100089 CHINA Tel: (86 10)6841 2211 Fax: (86 10)68418002

Set amidst charming landscaped gardens, the award-winning Shangri-La Hotel, Beijing, is one of the most elegant deluxe hotels in the city. Located near the financial district and Technology Park (the Silicon Valley of Beijing) it is also close to the State Guest House and historical Summer Palace.

CONFERENCE DATES: May 21-24, 2006

SUGGESTED DRESS: Business/Business Casual

VISA INFORMATION: NON CHINESE CITIZENS NEED A VISA TO ENTER CHINA. All participants will be responsible for obtaining an appropriate visa from Chinese consular authorities. For detailed information on how to obtain your visa, please visit www.china-embassy.org/eng/hzqz/default.htm. You only need a single trip visit for this event.

HOTEL ACCOMMODATIONS: We have reserved a limited block of rooms with the hotel at a special discounted rate for our attendees. To secure your accommodations, please contact the hotel BY APRIL 21, 2006 and be sure to mention that you are a Strategic Research Institute delegate.
Featuring Over 75 Speakers!
Your Gateway to the World’s Fastest Growing Pharmaceutical Market

IMPACT CHINA II:
PHARMACEUTICAL R&D
GLOBAL SUMMIT
MAY 21 - 24, 2006
SHANGRI-LA HOTEL BEIJING
BEIJING, CHINA

REGISTRATION FORM
333 Seventh Avenue, 9th Floor, New York, NY 10001
Tel: 212-967-0095 or 800-599-4950 • Fax: 212-967-8021

Please register the following delegate for CONFERENCE ONLY (by March 31, 2006; $1695 thereafter)..............................$1395

Please register the following delegate for CONFERENCE + WORKSHOP (by March 31, 2006; $1895 thereafter)......$1595

Please register the following university, hospital, or government employee (includes pre-conference workshop).............. $895

Name: ________________________________________________
Title: ________________________________________________
Company: ____________________________________________
Full Mailing Address: __________________________________
City/State/Zip Code: _________________________________
Email Address: _______________________________________
Phone: ____________________________
Fax: ______________________________

Payment enclosed □ Bill my company
Charge my: □ American Express □ Visa □ MasterCard
□ Diners Club □ Discover

Card# ________________________________
Expiration Date: Month_________ Year __________

Name (as shown on card) _______________________________________

Return Service Requested

WWW.SRINSTITUTE.COM/CHINA

CS370